The Insides Company is a pioneer in chyme reinfusion therapy, focused on developing specialised medical devices that support patients with intestinal failure and conditions involving intestinal discontinuity. These include high-output stomas, enterocutaneous fistulas, and postoperative situations where the normal digestive pathway is interrupted.

Their flagship technology, The Insides System, is the first purpose-designed platform that enables the safe and controlled reinfusion of intestinal chyme back into the distal gut. By returning the patient's own digestive fluids—rather than discarding them, the system helps restore physiological digestion, improve hydration and nutrient absorption, and support the recovery of overall intestinal function.

The Insides Company's mission, "refeed and restore", reflects their commitment to advancing gut-preserving therapies and improving outcomes for patients who face prolonged nutritional losses or risk of intestinal failure. Through ongoing clinical collaboration and innovation, the company continues to expand global access to chyme reinfusion therapy and introduce a new standard of care for complex enteric conditions.